<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pulmo</journal-id><journal-title-group><journal-title xml:lang="ru">Пульмонология</journal-title><trans-title-group xml:lang="en"><trans-title>PULMONOLOGIYA</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0869-0189</issn><issn pub-type="epub">2541-9617</issn><publisher><publisher-name>Scientific and Practical Journal “PULMONOLOGIYA” LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18093/0869-0189-2008-0-5-108-112</article-id><article-id custom-type="elpub" pub-id-type="custom">pulmo-1859</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>Ингаляционные кортикостероиды при стабильной хронической обструктивной болезни легких: эволюция взглядов</article-title><trans-title-group xml:lang="en"><trans-title>Inhaled corticosteroids in stable chronic obstructive pulmonary disease: an evolution of opinions</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шмелев</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Shmelev</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Отдел пульмонологии ГУ ЦНИИТ РАМН</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>28</day><month>10</month><year>2008</year></pub-date><volume>0</volume><issue>5</issue><fpage>108</fpage><lpage>112</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шмелев Е.И., 2008</copyright-statement><copyright-year>2008</copyright-year><copyright-holder xml:lang="ru">Шмелев Е.И.</copyright-holder><copyright-holder xml:lang="en">Shmelev E.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.pulmonology.ru/pulm/article/view/1859">https://journal.pulmonology.ru/pulm/article/view/1859</self-uri><abstract><p>.</p></abstract><trans-abstract xml:lang="en"><p>.</p></trans-abstract><funding-group><funding-statement xml:lang="ru">Cтатья опубликована при финансовой поддержке компании "ГлаксоСмитКляйн".</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Vestbo J., Sorensen T., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819–1823.</mixed-citation><mixed-citation xml:lang="en">Vestbo J., Sorensen T., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819–1823.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Engl. J. Med. 1999; 340: 1948–1953.</mixed-citation><mixed-citation xml:lang="en">Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Engl. J. Med. 1999; 340: 1948–1953.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wise R., Connett J., Weinmann G. et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive lung disease. N. Engl. J. Med. 2000; 343: 1902–1909.</mixed-citation><mixed-citation xml:lang="en">Wise R., Connett J., Weinmann G. et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive lung disease. N. Engl. J. Med. 2000; 343: 1902–1909.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Paggiaro P.L., Dahle R., Bakran I. et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773–780.</mixed-citation><mixed-citation xml:lang="en">Paggiaro P.L., Dahle R., Bakran I. et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773–780.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Spencer S., Calverley P.M.A., Burge S., Jones P.W. Health status deterioration in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 122–128.</mixed-citation><mixed-citation xml:lang="en">Spencer S., Calverley P.M.A., Burge S., Jones P.W. Health status deterioration in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 122–128.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Baranuik J.N., Ali M., Brody D. et al. Glucocorticoids induce β2-andrenergic receptor function in human nasal mucosa. Am. J. Respir. Crit. Care Med. 1997; 155: 704–710.</mixed-citation><mixed-citation xml:lang="en">Baranuik J.N., Ali M., Brody D. et al. Glucocorticoids induce β2-andrenergic receptor function in human nasal mucosa. Am. J. Respir. Crit. Care Med. 1997; 155: 704–710.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Usmani O.S., Maneechotesuwan K., Adcock I.M. et al. Glucocorticoid receptor activation following inhaled fluticasone &amp; salmeterol. Am. J. Respir. Crit. Care Med. 2002; 165 (suppl. 8): A616.</mixed-citation><mixed-citation xml:lang="en">Usmani O.S., Maneechotesuwan K., Adcock I.M. et al. Glucocorticoid receptor activation following inhaled fluticasone &amp; salmeterol. Am. J. Respir. Crit. Care Med. 2002; 165 (suppl. 8): A616.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Calverley P.M.A., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–789.</mixed-citation><mixed-citation xml:lang="en">Calverley P.M.A., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–789.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jarad N.A., Wedzicha J.A., Burge P.S., Calverley P.M. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir. Med. 1999; 93: 161–166.</mixed-citation><mixed-citation xml:lang="en">Jarad N.A., Wedzicha J.A., Burge P.S., Calverley P.M. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir. Med. 1999; 93: 161–166.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Vincken W., van Noord J.A., Greefhorst A.P. et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209–216.</mixed-citation><mixed-citation xml:lang="en">Vincken W., van Noord J.A., Greefhorst A.P. et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209–216.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Casaburi R., Mahler D.A., Jones P.W. et al. A long-term evaluation of oncedaily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217–224.</mixed-citation><mixed-citation xml:lang="en">Casaburi R., Mahler D.A., Jones P.W. et al. A long-term evaluation of oncedaily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217–224.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Powrie D.J., Wilkinson T.M.A., Donaldson G.C. et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 30: 472–478.</mixed-citation><mixed-citation xml:lang="en">Powrie D.J., Wilkinson T.M.A., Donaldson G.C. et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 30: 472–478.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bourbeau J., Christodoulopoulos P., Maltais F. et al. Effect of salmeterol / fluticasone propionate on airway inflammation in COPD: a randomized controlled trial. Thorax 2007; 62: 938–943.</mixed-citation><mixed-citation xml:lang="en">Bourbeau J., Christodoulopoulos P., Maltais F. et al. Effect of salmeterol / fluticasone propionate on airway inflammation in COPD: a randomized controlled trial. Thorax 2007; 62: 938–943.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Jeffery P. Anti-inflammatory effects of inhaled corticosteroids in chronic obstructive pulmonary disease: similarities and differences to asthma. Expert. Opin. Invest. Drugs 2005; 14: 619–632.</mixed-citation><mixed-citation xml:lang="en">Jeffery P. Anti-inflammatory effects of inhaled corticosteroids in chronic obstructive pulmonary disease: similarities and differences to asthma. Expert. Opin. Invest. Drugs 2005; 14: 619–632.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Barr R.G., Bourbeau J., Camargo C.A., Ram F.S. Tiotropium for stable chronic obstructive pulmonary disease: A metaanalysis. Thorax 2006; 61: 854–862.</mixed-citation><mixed-citation xml:lang="en">Barr R.G., Bourbeau J., Camargo C.A., Ram F.S. Tiotropium for stable chronic obstructive pulmonary disease: A metaanalysis. Thorax 2006; 61: 854–862.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Aaron S.D., Vandemheen K.L., Fergusson D. et al. Canadian Thoracic Society / Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545–555.</mixed-citation><mixed-citation xml:lang="en">Aaron S.D., Vandemheen K.L., Fergusson D. et al. Canadian Thoracic Society / Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545–555.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
